New Drug Reduces Epilepsy Seizures by 91% in Children with Dravet Syndrome

A new drug called zorevunersen has demonstrated extraordinary results in reducing seizures in children with Dravet syndrome, one of the most severe and treatment-resistant forms of epilepsy. Published in the New England Journal of Medicine, the study showed up to a 91% reduction in seizure frequency over a three-year period.

Dravet syndrome is a rare genetic epilepsy condition that typically begins in the first year of life. Children with this condition experience frequent and prolonged seizures that are often resistant to existing medications. The condition can lead to developmental delays, cognitive impairment, and carries a significant risk of sudden unexpected death in epilepsy.

“Published in the New England Journal of Medicine, the study showed up to a 91% reduction in seizure frequency over a three-year period.”

The research was led by Professor Helen Cross at Great Ormond Street Hospital in London, one of the world's leading centres for paediatric neurology. Prof Cross and her team tracked children receiving zorevunersen over an extended period, finding that the dramatic reduction in seizures was sustained over the full three years of the study, not just in the short term.

The mechanism of zorevunersen represents a new approach to treating genetic epilepsy. Rather than simply suppressing seizure activity as traditional anti-epileptic drugs do, the medication works at the genetic level to address the underlying cause of the condition. This targeted approach explains why the results have been so much more dramatic than those achieved with conventional treatments.

For families living with Dravet syndrome, these results represent a transformation in what is possible. Parents of children in the trial reported not just fewer seizures, but improvements in their children's alertness, engagement, and overall development — changes that extend far beyond seizure counts on a medical chart.

The findings have generated enormous interest in the epilepsy research community and among patient advocacy groups. If zorevunersen receives regulatory approval, it could become the first treatment to offer children with Dravet syndrome a realistic prospect of a life largely free from the devastating impact of constant seizures.